Elutia Inc. (ELUT) Stock Price & Analysis
Elutia Inc. (ELUT) fell 2.04% to USD 0.97 as of June 10, 2026 at 10:55 UTC, according to Nexqual real-time market data.
ELUT last closed at USD 0.99; the session ranged USD 0.96–1.02 on volume of 61,519 shares. Market capitalization is $42.88M, with a 52-week range of USD 0.5–2.64 (NCM). Source: Nexqual, June 10, 2026 at 10:55 UTC.
Key Statistics (as of June 10, 2026 at 10:55 UTC)
| Price | USD 0.97 |
|---|---|
| Change | ▼ 2.04% (down) |
| Previous Close | USD 0.99 |
| Open | USD 1.02 |
| Day Range | USD 0.96 – 1.02 |
| 52-Week Range | USD 0.5 – 2.64 |
| Volume | 61,519 shares |
| Market Cap | $42.88M |
| Exchange | NCM |
Technical Analysis (ELUT)
Nexqual's technical model rates ELUT "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 10:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.68 (neutral) |
| vs SMA50 | Below (USD 1.08) |
| MACD | -0.02 (negative) |
Analyst Ratings (ELUT)
Wall Street analysts rate ELUT "None" based on 1 analysts, with a mean price target of USD 5 (range USD 5–5), per Nexqual as of June 10, 2026 at 10:55 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 5 |
| High Target | USD 5 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ELUT)
| Next Earnings Date | 2026-08-14 |
|---|---|
| Revenue Estimate | $2.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.17 vs est -0.15 ▼ miss |
| 2025-12-31 | USD 1.48 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.16 ▲ beat |
| 2025-06-30 | USD -0.23 vs est -0.17 ▼ miss |
Source: Nexqual, June 10, 2026 at 10:55 UTC.
Financials & Fundamentals (ELUT)
| Total Revenue | $12.46M |
|---|---|
| Revenue Growth (YoY) | -48.40% |
| Gross Margin | +56.33% |
| Operating Margin | -184.39% |
| Profit Margin | +400.16% |
| Debt / Equity | 18.73 |
| Current Ratio | 2.05 |
| Total Cash | $28.49M |
| Total Debt | $4.22M |
Source: Nexqual, June 10, 2026 at 10:55 UTC.
Financial Health Score (ELUT)
Nexqual rates Elutia Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 10:55 UTC.
| Growth | Critical — Revenue -50% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $28M cash vs $4M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (ELUT)
| Insider Ownership | +3.40% |
|---|---|
| Institutional Ownership | +45.72% |
| Shares Outstanding | 44.21M |
| Float | 25.02M |
| Short % of Float | +0.11% |
Source: Nexqual, June 10, 2026 at 10:55 UTC.
Leadership (ELUT)
Elutia Inc. is led by C. Randal Mills (age 53), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 10:55 UTC.
| Co-Founder, President, CEO & Director | C. Randal Mills (age 53) |
|---|---|
| Chief Financial Officer | Matthew B. Ferguson (age 57) |
| Chief Scientific Officer | Michelle LeRoux Williams (age 50) |
Major Backers & Investors (ELUT)
Notable institutional backers of Elutia Inc. include AIGH Capital Management LLC, Nantahala Capital Management, LLC, Knollwood Investment Advisory, LLC, according to Nexqual as of June 10, 2026 at 10:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.13% |
| Nantahala Capital Management, LLC | 7.2% |
| Knollwood Investment Advisory, LLC | 5.78% |
| SilverArc Capital Management, LLC | 5.65% |
| Perkins Capital Management, Inc. | 1.71% |
| Corient Private Wealth LLC | 0.56% |
| Fidelity | 0.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.64% |
| Geode Capital | 0.66% |
| BlackRock | 0.45% |
Source: Nexqual, June 10, 2026 at 10:55 UTC.
From Elutia Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications.
- The company operates in two segments, Women's Health and Cardiovascular.
- Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
- The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MODD | Modular Medical, Inc. | USD 4.67 | ▲ 0.65% |
| HLP | Hongli Group Inc. | USD 0.48 | ▼ 8.75% |
| OIO | OIO Group | USD 2.03 | ▲ 5.18% |
| MGRX | Mangoceuticals, Inc. | USD 0.34 | ▼ 4.48% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:55 UTC. This page is informational and not investment advice.